Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hymenialdisine
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
Hymenialdisine is a marine sponge-derived pyrroloazepine alkaloid with pan kinase inhibitory activity. It acts as a natural inhibitor of multiple protein kinases, including those involved in NF-kB and MAPK signaling pathways, and has demonstrated anticancer, anti-inflammatory, and bone-protective effects. In preclinical studies, hymenialdisine suppresses osteoclastogenesis while promoting osteoblast differentiation, suggesting potential applications in osteoporosis treatment. It is not approved for any clinical use.[4][5][7]
- Other names
- 10Z-Hymenialdisine(Z)-Hymenialdisine82005-12-7 (CAS)95569-43-0 (CAS)Z-HYMENIALDISINE[2][3][6]
02
Targets
CSNK1G3 (Casein kinase 1 gamma 3)CDK2 (Cyclin-dependent kinase 2)GSK3 (Glycogen synthase kinase 3 beta)PK (Pyruvate kinase)
Beyond the preview
Go deeper on hymenialdisine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hymenialdisine.